Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2

Table 2 Analysis of metastatic lung nodules according to control and treatment groups.

Groups	Areas of metastatic nodule (mean, mm²)	p-value
Control	0.61–4.04 (1.09)	-
Celecoxib 25 mg/kg	0.05–3.81 (1.48)	0.3607
Celecoxib 75 mg/kg	0.07–1.37 (0.81)	0.0295
RT	0.20–0.45 (0.31)	0.0181
RT + Celecoxib 25 mg/kg	0.04–1.64 (0.50)	0.0238
RT + Celecoxib 75 mg/kg	0.03–0.22 (0.13)	0.0675

ISSN: 1756-9966